In this work, we provide an overview of the preclinical studies based on the combined application of cisplatin (a conventional chemotherapy agent) and EZH2 (Enhancer of Zeste Homolog 2) inhibitors (targeted epigenetics therapy) in different cancer types. Here, EZH2 is linked to cancer.